Praluzatamab Ravtansine, a CD166-Targeting Antibody– Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial

Boni V, Fidler MJ, Arkenau HT, et al. Praluzatamab ravtansine, a CD166-targeting antibody-drug conjugate, in patients with advanced solid tumors: an open-label phase 1/2 trial [published online ahead of print, 2022 Feb 14]. Clin Cancer Res. 2022;clincanres.3656.2021. doi:10.1158/1078-0432.CCR-21-3656